Shield Therapeutics plc (FRA:1JS)
Germany · Delayed Price · Currency is EUR | Market Cap | 138.64M |
| Revenue (ttm) | 35.33M |
| Net Income (ttm) | -18.09M |
| Shares Out | n/a |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,000 |
| Average Volume | 22,961 |
| Open | 0.1260 |
| Previous Close | 0.1260 |
| Day's Range | 0.1260 - 0.1350 |
| 52-Week Range | 0.0225 - 0.1400 |
| Beta | n/a |
| RSI | 53.81 |
| Earnings Date | n/a |
About Shield Therapeutics
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom. [Read more]
Financial Performance
In 2024, Shield Therapeutics's revenue was $32.18 million, an increase of 145.93% compared to the previous year's $13.09 million. Losses were -$27.18 million, -18.36% less than in 2023.
Financial numbers in USD Financial StatementsNews
Shield Therapeutics plc (SHIEF) Q3 2025 Sales/ Trading Statement Call - Slideshow
2025-10-29. The following slide deck was published by Shield Therapeutics plc in conjunction with this event.
OTC Markets Group Welcomes Shield Therapeutics PLC to OTCQX
NEW YORK, May 17, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Shield Therapeutics PLC (LSE: STXS; OT...